Amarin Corp Plc\Uk
$5.60B- Market cap
- $5.73B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: AMRN stock price at premium vs AMAT $13.63 current versus $6.55 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMAT's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · AMAT FY 2025 (ended Oct 26, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Capital structure 98% equity / 2% debt · EV / Revenue 12.65x · EV / EBITDA 36.25x
AMAT carries the larger enterprise value at $358.84B against $5.60B; AMAT trades on the lower EV / Revenue multiple (12.65x vs 26.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
APPLIED MATERIALS INC /DE · implied price per share
Bear
$120.65
Base
$147.28
Bull
$167.98
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
0.32x
Net debt / EBITDA
Leverage against operating earnings
3.79x
-0.20x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$8.57B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
LAM RESEARCH CORP
AMRN vs LRCX
ASML HOLDING NV
AMRN vs ASML
TERADYNE, INC
AMRN vs TER
MKS INSTRUMENTS INC
AMRN vs MKSI
KLA CORP
AMRN vs KLAC
SKYWORKS SOLUTIONS, INC.
AMRN vs SWKS
$177.39M
$6.56B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMRN can reverse its revenue decline and materially improve operating margins and ROIC, then hold or accumulate selectively; otherwise, the data argues for caution because the stock trades well above AMAT-implied value despite weaker profitability and leverage metrics.
AMRN is trading at $16.37 versus a AMAT-implied price of $8.69, implying 46.9% downside. Its current price also sits above the top of the historical band at $18.01? No, it sits within the historical band of $14.73 to $18.01, but still well above AMAT-implied valuation.
Supporting Metrics